Cargando…

Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation

Gut microbiota and short‐chain fatty acids (SCFAs) are associated with the development of various human diseases. In this study, we examined the role of astragaloside IV in modulating mouse gut microbiota structure and the generation of SCFAs, as well as in slow transit constipation (STC). An STC mo...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qiulan, Han, Changpeng, Huang, Liang, Yang, Haojie, Hu, Jiancong, Chen, Huaxian, Dou, Ruoxu, Ren, Donglin, Lin, Hongcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417726/
https://www.ncbi.nlm.nih.gov/pubmed/32628809
http://dx.doi.org/10.1111/jcmm.15586
_version_ 1783569557466644480
author He, Qiulan
Han, Changpeng
Huang, Liang
Yang, Haojie
Hu, Jiancong
Chen, Huaxian
Dou, Ruoxu
Ren, Donglin
Lin, Hongcheng
author_facet He, Qiulan
Han, Changpeng
Huang, Liang
Yang, Haojie
Hu, Jiancong
Chen, Huaxian
Dou, Ruoxu
Ren, Donglin
Lin, Hongcheng
author_sort He, Qiulan
collection PubMed
description Gut microbiota and short‐chain fatty acids (SCFAs) are associated with the development of various human diseases. In this study, we examined the role of astragaloside IV in modulating mouse gut microbiota structure and the generation of SCFAs, as well as in slow transit constipation (STC). An STC model was established by treating mice with loperamide, in which the therapeutic effects of astragaloside IV were evaluated. The microbiota community structure and SCFA content were analysed by 16S rRNA gene sequencing and gas chromatography‐mass spectrometry, respectively. The influence of butyrate on STC was assessed using a mouse model and Cajal cells (ICC). Astragaloside IV promoted defecation, improved intestinal mobility, suppressed ICC loss and alleviated colonic lesions in STC mice. Alterations in gut microbiota community structure in STC mice, such as decreased Lactobacillus reuteri diversity, were improved following astragaloside IV treatment. Moreover, astragaloside IV up‐regulated butyric acid and valeric acid, but decreased isovaleric acid, in STC mouse stools. Butyrate promoted defecation, improved intestinal mobility, and enhanced ICC proliferation by regulating the AKT–NF‐κB signalling pathway. Astragaloside IV promoted intestinal transit in STC mice and inhibited ICC loss by regulating the gut microbiota community structure and generating butyric acid.
format Online
Article
Text
id pubmed-7417726
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74177262020-08-11 Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation He, Qiulan Han, Changpeng Huang, Liang Yang, Haojie Hu, Jiancong Chen, Huaxian Dou, Ruoxu Ren, Donglin Lin, Hongcheng J Cell Mol Med Original Articles Gut microbiota and short‐chain fatty acids (SCFAs) are associated with the development of various human diseases. In this study, we examined the role of astragaloside IV in modulating mouse gut microbiota structure and the generation of SCFAs, as well as in slow transit constipation (STC). An STC model was established by treating mice with loperamide, in which the therapeutic effects of astragaloside IV were evaluated. The microbiota community structure and SCFA content were analysed by 16S rRNA gene sequencing and gas chromatography‐mass spectrometry, respectively. The influence of butyrate on STC was assessed using a mouse model and Cajal cells (ICC). Astragaloside IV promoted defecation, improved intestinal mobility, suppressed ICC loss and alleviated colonic lesions in STC mice. Alterations in gut microbiota community structure in STC mice, such as decreased Lactobacillus reuteri diversity, were improved following astragaloside IV treatment. Moreover, astragaloside IV up‐regulated butyric acid and valeric acid, but decreased isovaleric acid, in STC mouse stools. Butyrate promoted defecation, improved intestinal mobility, and enhanced ICC proliferation by regulating the AKT–NF‐κB signalling pathway. Astragaloside IV promoted intestinal transit in STC mice and inhibited ICC loss by regulating the gut microbiota community structure and generating butyric acid. John Wiley and Sons Inc. 2020-07-06 2020-08 /pmc/articles/PMC7417726/ /pubmed/32628809 http://dx.doi.org/10.1111/jcmm.15586 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
He, Qiulan
Han, Changpeng
Huang, Liang
Yang, Haojie
Hu, Jiancong
Chen, Huaxian
Dou, Ruoxu
Ren, Donglin
Lin, Hongcheng
Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
title Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
title_full Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
title_fullStr Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
title_full_unstemmed Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
title_short Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
title_sort astragaloside iv alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417726/
https://www.ncbi.nlm.nih.gov/pubmed/32628809
http://dx.doi.org/10.1111/jcmm.15586
work_keys_str_mv AT heqiulan astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT hanchangpeng astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT huangliang astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT yanghaojie astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT hujiancong astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT chenhuaxian astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT douruoxu astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT rendonglin astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration
AT linhongcheng astragalosideivalleviatesmouseslowtransitconstipationbymodulatinggutmicrobiotaprofileandpromotingbutyricacidgeneration